Oncology and Hematology

225-240 of 625

• 

  RestartResume

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  RestartResume

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  MinuteCE®

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Applications of Emerging Data in Resectable NSCLC

  RestartResume

  Applications of Emerging Data in Resectable NSCLC

  MinuteCE®

  Applications of Emerging Data in Resectable NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  The Current Therapeutic Landscape in Unresectable Stage III NSCLC

  RestartResume

  The Current Therapeutic Landscape in Unresectable Stage III NSCLC

  MinuteCE®

  The Current Therapeutic Landscape in Unresectable Stage III NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  RestartResume

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  MinuteCE®

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  MinuteCE®

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  RestartResume

  HER2-Driven Strategies in Metastatic NSCLC

  MinuteCE®

  HER2-Driven Strategies in Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  MET and Other Emerging Targets in Metastatic NSCLC

  RestartResume

  MET and Other Emerging Targets in Metastatic NSCLC

  MinuteCE®

  MET and Other Emerging Targets in Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC

  RestartResume

  Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC

  MinuteCE®

  Emerging Therapeutic Developments in Non-Targetable Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  RestartResume

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  MinuteCE®

  Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  RestartResume

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  MinuteCE®

  Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma

  1.00 program credit

  • 

    

    John M. Kirkwood, MD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  1.00 program credit

• 

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  RestartResume

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  MinuteCE®

  Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  MinuteCE®

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  RestartResume

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  MinuteCE®

  Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed BRAF-Mutant Stage IV Melanoma

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  MinuteCE®

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• Previous
• 1
• 2
• …
• 13
• 14
• 15
• 16
• 17
• …
• 39
• 40
• Next